TY - JOUR
T1 - Central sensitization has major impact on quality of life in patients with axial spondyloarthritis
AU - Kieskamp, Stan C.
AU - Paap, Davy
AU - Carbo, Marlies J.G.
AU - Wink, Freke
AU - Bos, Reinhard
AU - Bootsma, Hendrika
AU - Arends, Suzanne
AU - Spoorenberg, Anneke
N1 - Funding Information:
Disclosure statement: F.W. has received research grants from Novartis, and consulting fees from Pfizer. S.A. has received research grants from Pfizer. A.S. has received research grants from Abbvie, Pfizer, UCB and Novartis, and consulting fees from Abbvie, Pfizer, MSD, UCB, and Novartis. The other authors declare that they have no competing interests.
Publisher Copyright:
© 2021
PY - 2022/2
Y1 - 2022/2
N2 - Introduction: Persistent pain has large potential impact on quality of life (QoL). During the course of the disease, many patients with axial spondyloarthritis (axSpA) report persistent pain. Central sensitization (CS) may explain part of this chronic pain. However, the role of CS in relation to QoL has been sparsely studied in axSpA. Therefore, our aim was to explore the relationship between CS and QoL in patients with axSpA.Methods: Consecutive outpatients from the Groningen Leeuwarden axSpA (GLAS) cohort completed the Central Sensitization Inventory (CSI; range 0–100) and the AS Quality of Life (ASQoL; range 0–18). Multivariable linear regression analysis was used to explore the relationship between CSI and ASQoL scores correcting for potential confounders.Results: Of the 178 included axSpA patients, mean CSI score was 38.0 ± 14.1 and 45% scored ≥40, which indicates a high probability of CS. Mean ASQoL score was 6.0 ± 5.3 and mean ASDASCRP 2.1 ± 1.0. A CSI score ≥40 was significantly associated with higher ASQoL score (mean 9.7 vs. 3.3), higher ASDASCRP (mean 2.6 vs. 1.7), female gender (60% vs. 29%) and more often entheseal involvement (61% vs. 26%). In univariable analysis, CSI score explained a large proportion of the variation in ASQoL (B = 0.06, 95%CI: 0.05–0.07; R2=0.46). This association remained significant after correction for ASDASCRP, gender, entheseal involvement, comorbidities, symptom duration, smoking status, BMI class and educational level (B = 0.04, 95%CI: 0.03–0.05).Conclusion: CS is strongly related to patient-reported QoL in patients with axSpA independently from other patient- and disease-related aspects.
AB - Introduction: Persistent pain has large potential impact on quality of life (QoL). During the course of the disease, many patients with axial spondyloarthritis (axSpA) report persistent pain. Central sensitization (CS) may explain part of this chronic pain. However, the role of CS in relation to QoL has been sparsely studied in axSpA. Therefore, our aim was to explore the relationship between CS and QoL in patients with axSpA.Methods: Consecutive outpatients from the Groningen Leeuwarden axSpA (GLAS) cohort completed the Central Sensitization Inventory (CSI; range 0–100) and the AS Quality of Life (ASQoL; range 0–18). Multivariable linear regression analysis was used to explore the relationship between CSI and ASQoL scores correcting for potential confounders.Results: Of the 178 included axSpA patients, mean CSI score was 38.0 ± 14.1 and 45% scored ≥40, which indicates a high probability of CS. Mean ASQoL score was 6.0 ± 5.3 and mean ASDASCRP 2.1 ± 1.0. A CSI score ≥40 was significantly associated with higher ASQoL score (mean 9.7 vs. 3.3), higher ASDASCRP (mean 2.6 vs. 1.7), female gender (60% vs. 29%) and more often entheseal involvement (61% vs. 26%). In univariable analysis, CSI score explained a large proportion of the variation in ASQoL (B = 0.06, 95%CI: 0.05–0.07; R2=0.46). This association remained significant after correction for ASDASCRP, gender, entheseal involvement, comorbidities, symptom duration, smoking status, BMI class and educational level (B = 0.04, 95%CI: 0.03–0.05).Conclusion: CS is strongly related to patient-reported QoL in patients with axSpA independently from other patient- and disease-related aspects.
KW - Axial Spondyloarthritis
KW - Central Sensitization
KW - Pain
KW - Quality of Life
U2 - 10.1016/j.semarthrit.2021.11.006
DO - 10.1016/j.semarthrit.2021.11.006
M3 - Article
C2 - 35033996
AN - SCOPUS:85122670178
SN - 0049-0172
VL - 52
JO - SEMINARS IN ARTHRITIS AND RHEUMATISM
JF - SEMINARS IN ARTHRITIS AND RHEUMATISM
M1 - 151933
ER -